Agnès Bernet
{{short description|French cell biologist (born 1968)}}
{{Infobox person
| name = Agnès Bernet
| image =
| caption =
| othername =
| birth_name =
| birth_date = 1968
| birth_place =
| death_date =
| death_place =
| burial_place =
| nationality = French
| alma_mater = University Claude Bernard Lyon I
| occupation = Scientific director, Netris Pharma
| years_active =
| known_for = Co-founder of NETRIS Pharma
| spouse =
}}
Agnès Bernet, (born 1968) is a French cell biologist and professor of cancer biology at the University Claude Bernard Lyon I. A co-founder of NETRIS Pharma, she has led within the Laboratory of Apoptosis, Cancer and Development, the research team that validated the use of interference ligand/dependence receptors as novel targeted therapies for cancer.{{Cite web |title=Chairman of the Board and Senior Management |url=https://www.netrispharma.com/chairman-of-the-board-and-senior-management/ |access-date=2022-06-15 |website=NETRIS PHARMA |language=fr-FR}}
Life and work
Bernet earned her PhD at University Claude Bernard Lyon I in 1994 with the thesis Etude, par recombinaison homologue, de régions régulatrices de l'expression des gènes de globine alpha humains (Study, by homologous recombination, of regulatory regions of the expression of human alpha globin genes). Her research focused on the study of two regions that may be involved in the activation of human alpha globin genes during erythroid differentiation.{{Cite thesis |title=Etude, par recombinaison homologue, de régions régulatrices de l'expression des gènes de globine α humains |url=https://www.theses.fr/1994LYO10327 |publisher=Claude Bernard University Lyon 1 |date=1994-01-01 |degree=Doctoral |first=Agnès |last=Bernet}}
In 2008, she co-founded the company Netris Pharma SAS, where she serves as scientific director and coordinates numerous research projects concerning clinical therapies relating to cancer. In particular, her work on Netrin-1, the antibody developed by her team, is an antitumor product that has been tested in humans in clinical trials at the Center Léon Bérard.{{Cite web |title=Zoom sur Agnès BERNET, Prix Irène Joliot-Curie 2015 {{!}} Cancéropôle Lyon Auvergne Rhône-Alpes – CLARA |url=https://archive.wikiwix.com/cache/index2.php?url=http://www.canceropole-clara.com/zoom-sur-agnes-bernet-prix-irene-joliot-curie-2015/#federation=archive.wikiwix.com |access-date=2022-06-15 |website=archive.wikiwix.com |language=fr}}
Her work has focused on a new therapeutic target, dependence receptors. These are pairs of receptors/ligands that are deregulated in cancers. The first prototype therapeutic molecule was an antibody against the ligand Netrin-1, overexpressed in many types of cancer. This antibody causes the death of tumor cells.{{Cite web |title=Agnes Bernet |url=https://www.researchgate.net/profile/Agnes-Bernet |access-date=2020-06-15 |website=Research gate}}
Bernet was named a junior member of the Institut Universitaire de France in 2008, which was a five-year appointment.{{Cite web |last=Institut Universitaire de France |title=About the 2008 nominations at the IUF |url=http://smai.emath.fr/spip.php?breve114&lang=fr |language=fr}} In 2015, she received the Irène Joliot-Curie Prize in the Women and Business category for her work in both teaching and researching cancer therapies.
Selected publications
- Bernet, A. (1994). Etude, par recombinaison homologue, de régions régulatrices de l'expression des gènes de globine α humains (Doctoral dissertation, University Claude Bernard Lyon I). (In French).
- Bernet, A., Mazelin, L., Coissieux, M. M., Gadot, N., Ackerman, S. L., Scoazec, J. Y., & Mehlen, P. (2007). Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies. Gastroenterology, 133(6), 1840-1848.
- Bernet, A., & Mehlen, P. (2007). Dependence receptors: when apoptosis controls tumor progression. Bulletin du cancer, 94(4), 10012-10017.
- Bernet, A., & Fitamant, J. (2008). Netrin-1 and its receptors in tumour growth promotion. Expert opinion on therapeutic targets, 12(8), 995-1007.
- Bellina, M., & Bernet, A. (2022). La nétrine-1, une nouvelle cible antitumorale (Netrin-1, a new antitumor target). médecine/sciences, 38(4), 351-358. (In French).
Awards and distinctions
- Knight of the Legion of Honor{{Cite web |date=2022-03-14 |title=PR. BERNET APPOINTED AS KNIGHT OF THE LEGION OF HONOR |url=https://www.netrispharma.com/actualites/pr-bernet-appointed-as-knight-of-the-legion-of-honor/ |access-date=2022-06-15 |website=NETRIS PHARMA |language=fr-FR}}
- Irène Joliot-Curie Prize (2015){{Cite web |title=Prix Irène Joliot-Curie 2015 : trois femmes d'exception récompensées - ESR : enseignementsup-recherche.gouv.fr |url=https://archive.wikiwix.com/cache/index2.php?url=http://www.enseignementsup-recherche.gouv.fr/pid24643-cid95579/prix-irene-joliot-curie-2015-trois-femmes-d-exception-recompensees.html#federation=archive.wikiwix.com |access-date=2022-06-15 |website=archive.wikiwix.com |language=fr}}
- Bernet is listed as an inventor of several patents{{Cite web |title=Agnes Bernet Inventions, Patents and Patent Applications - Justia Patents Search |url=https://patents.justia.com/inventor/agnes-bernet |access-date=2022-06-15 |website=patents.justia.com}}
References
{{Reflist}}
{{Authority control}}
{{DEFAULTSORT:Bernet, Agnes}}
Category:Place of birth missing (living people)
Category:21st-century French women scientists
Category:French women biologists
Category:21st-century French biologists